Medical Imaging

PathAI: The Hidden Advantage Top Biopharma Leaders Are Using to Accelerate R&D

PathAI - ai tools in healthcare

Feature Categories

PathAI is a leading AI-powered digital pathology platform that enhances diagnostic accuracy and accelerates drug development. Its cloud-native AISight® Image Management System integrates with clinical and lab workflows to combine whole-slide imaging with validated AI algorithms—such as TumorDetect, AIM-Tumor Cellularity, ArtifactDetect, and AIM-MASH—for consistent, quantitative assessment of pathology samples.

PathAI’s solutions support translational research, biomarker discovery, and endpoint measurement in clinical trials. Their Trial Services offerings include AI-driven biomarker scoring, histologic endpoint analysis, and remote central pathology review compliant with GCP/GCLP guidelines.

Trusted by biopharma, labs, and CROs, PathAI is enabling scalable, FDA/EMA-compatible digital pathology workflows that reduce subjective variability, improve quality, and accelerate translation from tissue to therapy.

Why Leading Healthcare Teams Trust PathAI

  • Strategic Acquisition by Quest Diagnostics
    In June 2024, Quest Diagnostics completed the acquisition of select PathAI Diagnostics’ lab assets, including a state-of-the-art digitized laboratory in Memphis, rebranded as AmeriPath. This facility now serves as Quest’s national AI and digital R&D center, supporting specialty pathology businesses and accelerating the adoption of AI and digital pathology in cancer diagnosis.

  • Exclusive Collaboration with Roche Tissue Diagnostics
    PathAI entered into an exclusive agreement with Roche Tissue Diagnostics to develop AI-enabled digital pathology algorithms for companion diagnostics. This collaboration positions PathAI as a key player in advancing AI-powered companion diagnostics in the oncology space.

  • Partnership with ConcertAI for Real-World Data Solutions
    PathAI and ConcertAI have partnered to create a first-in-class quantitative histopathology and curated clinical real-world data solution. This collaboration combines PathAI’s proprietary Tumor Microenvironment Human-Interpretable Features (HIFs) with ConcertAI’s Patient360™ and RWD360™ products, supporting life sciences partners in exploring novel hypotheses.

  • Advanced AI-Powered Pathology Platform
    PathAI’s AISight™ digital pathology image management system and algorithm portfolio are licensed to Quest Diagnostics to support pathology laboratories and customer sites in the United States. This platform enhances the accuracy and efficiency of cancer diagnosis through AI-driven analysis.

  • Commitment to Biopharmaceutical Clients
    PathAI continues to support its biopharmaceutical clients with end-to-end clinical trial services capabilities at its separate research laboratory in Memphis, Tennessee. This commitment ensures ongoing innovation and support for drug development and clinical research.

Features

Website: https://www.pathai.com/
Deployment Time and Ease of Use: Rapid Implementation: PathAI's platform is HIPAA-compliant, secure, and customizable, enabling rapid deployment in healthcare settings. User-Friendly Interface: A significant majority (90%) of surveyed customers cited ease of use as a top reason for preferring PathAI. The platform's simple, streamlined interface allows healthcare professionals to quickly learn how to navigate the system without extensive training. Seamless Integration: PathAI seamlessly integrates into existing hospital workflows, with 88% of surveyed customers highlighting its positive impact on care coordination and team efficiency.
Therapeutic Area: Primarily oncology and liver (e.g. MASH), but also applicable across GI, dermatology, immunology, cardiology, and rare diseases
Scalability: Used by 90% of top-15 biopharma companies; supported by PathAI’s network of 550+ board-certified pathologists, millions of annotations, and high-performance GPU‑based inference infrastructure
Clinical Trial Support: Provides central pathology services for endpoint measurement, biomarker analytics, and patient enrichment in trials (e.g. IBD, GI, oncology) using AI scoring models and study-centric workflows
Competitive Comparisons: Vs. Tempus: PathAI offers a broader range of predictive models and real-world data analytics, while Tempus focuses more on genomic data and precision medicine. Vs. OM1: While OM1 specializes in real-world evidence and predictive modeling, PathAI offers a comprehensive platform for acute care coordination and rapid decision-making in time-sensitive conditions. Vs. Skypoint AI Platform: Skypoint provides flexible GPU-powered AI pods, whereas PathAI specializes in healthcare-specific AI applications and real-time care coordination.
Unique AI Model Capabilities: FDA-Cleared Algorithms: PathAI offers over 50 FDA-cleared AI algorithms that analyze medical imaging data—including CT scans, EKGs, echocardiograms, and more—delivering real-time insights and automated assessments to accelerate diagnosis, streamline workflows, and support faster treatment decisions. Real-Time Communication: The platform enables real-time communication among multidisciplinary care teams, facilitating prompt patient access to life-saving treatments. Comprehensive Disease Detection: PathAI's platform is designed to detect a wide range of time-sensitive conditions, including large vessel occlusions, intracerebral hemorrhages, and other critical diseases, across various therapeutic areas such as neurology, cardiology, and trauma.
Integration and Compatibility: Integrates with LIS/LIMS, lab scanners, clinical trial data systems, and third-party AI algorithms via AISight IMS unified environment
Key Use Cases/ Target Users: AI-based biomarker quantification (e.g. PDL1, Ki-67) Histologic response scoring (e.g. AIM-MASH for liver biopsy) Central pathology review and endpoint measurement for clinical trials Translational research and digital pathology labs.
Pricing Model: Enterprise SaaS, demo available; contact for personalized quotes tailored to clinical or lab requirements.
Supported Data Types: Whole-slide pathology images (H&E, IHC, Z-stack, multi-stain), structured algorithm outputs, annotated regions of interest, pathology metadata.
Operational & Financial Impact: Improved Treatment Times: Implementation of PathAI's platform has been associated with a significant reduction in treatment times for large vessel occlusion patients. A study reported a 31-minute reduction in treatment time, which is crucial as every minute of delay in endovascular therapy has been linked to increased disability-adjusted life-years. Reduced Transfer Times: PathAI has decreased door-in-door-out times by nearly 50%, enhancing the speed at which patients receive care and significantly improving their outcomes. Enhanced Length of Stay Metrics: Hospitals utilizing PathAI have reported a reduction in hospital length of stay by 2.5 days and ICU length of stay by 3.5 days, contributing to cost savings and improved resource utilization. Increased Procedure Volume: The platform has been associated with a 16% increase in the number of appropriate procedures performed, indicating improved clinical decision-making and operational efficiency.
Deployment Model: SaaS (cloud-native), HIPAA- and CLIA‑, CAP‑, GCP/GCLP-compliant infrastructure designed for research and trial use cases

  • Watch Overview

Top 3 Pain Points PathAI Fixes in Healthcare

ProblemHow PathAI Solves It
1. Diagnostic inconsistency and interpretive biasUses validated AI algorithms to standardize tumor detection, biomarker scoring, and MASH evaluation
2. Manual clinical trail pathology review is slow and fragmentedOffers AI-augmented remote central pathology services (AISight®) integrated with GCP/GCLP workflows
3. Limited objective measurement for biomarker discoveryExtracts quantitative histologic features (e.g. TILs, fibrosis metrics, cellularity) at single-cell resolution

 

Feature Category Summary: PathAI

Feature CategorySummary
Regulatory-ReadyFDA cleared, CE marked, with proactive validation and change control plans for compliance
Clinical Trial SupportEMA-qualified AI tools aiding clinical trial biopsy assessment and endpoint evaluation
Supply Chain & QualityDoes not address supply chain, counterfeit detection, or manufacturing quality
Efficiency & Cost-SavingAutomates pathology workflows, reducing manual processes and improving turnaround times
Scalable / Enterprise-GradeCloud-native, scalable platforms deployed widely in healthcare systems and academic centers
HIPAA CompliantImplied compliance with healthcare privacy standards including HIPAA through clinical use
Clinically ValidatedClinically validated with regulatory clearances and superior performance against human benchmarks
EHR IntegrationIntegrates with lab information systems; limited or no direct broader EHR integration
Explainable AIProvides transparent, interpretable AI insights supporting pathologist decision-making
Real-Time AnalyticsSupports near real-time workflows and live collaboration in pathology

Tags

Share This AI Tool

Contact Us To Request Pricing or a Demo

Avatar

Stephen

hello@healthydata.science